OVIDE
LOE Approachingmalathion
NDATOPICALLOTION
Approved
Aug 1982
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
4/8 — Partial
OVIDE (malathion) is cholinesterase inhibitors [moa]. First approved in 1982.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OVIDE (malathion) is a topical lotion containing a cholinesterase inhibitor that has been approved since 1982. It is indicated for the treatment of head lice infestations by disrupting the nervous system of parasites. The drug works by inhibiting cholinesterase enzymes, leading to accumulation of acetylcholine and paralysis of the louse.
LOE Approaching7mo to LOE
With LOE imminent in 0.6 years and modest competitive pressure (25%), the brand team is likely operating in maintenance mode with constrained resources and limited growth opportunities.
Mechanism of Action
Cholinesterase Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion
Tumors Harboring NTRK Fusion
Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer
HR+ Advanced or Metastatic Breast Cancer
Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion
Solid Tumors Harboring NTRK Fusion
MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
Polycythemia Vera
An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)
TNBCTNBC - Triple-Negative Breast CancerTNBC, Triple Negative Breast Cancer
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.